X0202 SCHEDULE 13G 0001784547 XXXXXXXX LIVE Ordinary Shares, no par value 03/31/2026 0001849296 OKYO Pharma LTD G6724L116 107 Cheapside 9th Floor London X0 EC2V 6DN Rule 13d-1(b) Woodline Partners LP DE 3652190.00 0.00 3652190.00 0.00 3652190.00 N 7.0 IA PN OKYO Pharma LTD 9th Floor, 107 Cheapside, London EC2V 6DN, United Kingdom, EC2V 6DN Woodline Partners LP ("Woodline Partners" or the "Reporting Person"), a Delaware limited partnership, and the investment adviser to Woodline Master Fund LP (the "Woodline Fund"), with respect to the ordinary shares, no par value ("Ordinary Shares") of OKYO Pharma LTD (the "Company") directly held by the Woodline Fund; The filing of this statement should not be construed as an admission that any of the foregoing persons or the Reporting Person is, for the purposes of Section 13 of the Securities Exchange Act of 1934, the beneficial owner of the Ordinary Shares reported herein. The address of the business office of Woodline Partners is 4 Embarcadero Center, Suite 3450, San Francisco, CA 94111. Woodline Partners is a Delaware limited partnership. N IA The information required by Item 4(a) is set forth in Row 9 of the cover page for the Reporting Person and is incorporated herein by reference. The percentage set forth in this Schedule 13G is calculated based upon an aggregate of 52,479,257 Ordinary Shares, which is the sum of (i) 10,815,000 Ordinary Shares issued in the offering described in the Company's Prospectus filed pursuant to Rule 424(b)(5) with the Securities and Exchange Commission (the "SEC") on February 17, 2026; (ii) 1,109,060 Ordinary Shares issued pursuant to the partial exercise of the underwriters' option to purchase additional shares as reported in the Company's Report of Foreign Issuer on Form 6-K, filed with the SEC on March 12, 2026; and (iii) 40,555,197 Ordinary Shares outstanding as of February 9, 2026, as reported in the in the Company's Prospectus filed pursuant to Rule 424(b)(5) with the SEC on February 17, 2026. 7.0% The information required by Item 4(c)(i) is set forth in Row 5 of the cover page for the Reporting Person and is incorporated herein by reference. The information required by Item 4(c)(ii) is set forth in Row 6 of the cover page for the Reporting Person and is incorporated herein by reference. The information required by Item 4(c)(iii) is set forth in Row 7 of the cover page for the Reporting Person and is incorporated herein by reference. The information required by Item 4(c)(iv) is set forth in Row 8 of the cover page for the Reporting Person and is incorporated herein by reference. Y N See Item 2(a). The Woodline Fund has the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, more than 5% of the Ordinary Shares. Y Y Y N By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under ?? 240.14a-11. Woodline Partners LP /s/ Erin Mullen 05/15/2026